Page 178 - Quantitative Imaging of Small Tumours with Positron Emission Tomography

We assessed potential associations of PET quantitative parameters with clinical data (supplemental data). Several SUV and TLCU variants were significantly higher for patients with PSA levels above median (3.75 ng/ml) at PET/CT (p=0.01-0.04). For Gleason score and pre-treatment with ADT we found no significant association with quantitative PET parameters. Table 8.1: Patient characteristics. Characteristic Age at metastases Mean±SD Time from diagnosis to metastases Median (IQR) Gleason score 5 6 7 8 9 TNM-stage at diagnosis Stage 2 Stage 3 Stage 4 Primary treatment Surgery Surgery + radiotherapy Radiotherapy Radiotherapy + hormone therapy Brachytherapy Lymph node dissection Yes No PSA at metastases Median (IQR) Type of metastases Bone Lymph node Bone + Lymph node 67±6.7 years 46.2 (12.0-81.8) months 2 (5%) 5 (13%) 16 (41%) 10 (26%) 6 (16%) 20 (51%) 16 (41%) 3 (8%) 25 (63%) 4 (10%) 5 (13%) 3 (8%) 3 (8%) 13 (33%) 27 (68%) 3.75 (2.43-6.80) ng/ml 9 (23%) 30 (75%) 1 (3%) 8 Oligometastatic prostate cancer Table 8.2: Lesion-based values of PET parameters. Data are presented as median with IQR. MATV SUVmean-pvc TLCUpvc All lesions (n=50) 2.21 (1.58-3.28) 3.93 (3.01-5.34) 8.39 (5.24-15.43) Lymph node (n=37) 1.92 (1.40-2.74) 3.72 (3.12-5.25) 7.43 (4.77-13.06) Bone (n=13) 3.46 (2.68-8.96) 4.45 (2.80-5.55) 12.68 (7.52-50.33) p-valuea <0.001 0.816 0.009 aLymph node vs. bone 177